Forgot Password?
Return to Course Listing

CME: Best practices and emerging therapy in relapsed or refractory multiple myeloma


Activity Description / Statement of Need:

In this online CME self-learning program:

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. Myeloma is most common of the hematologic malignancies after non-Hodgkin lymphoma, with an incidence of a little over 32,000 and an annual mortality rate of just under 13,000. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites. Goals of care in MM are prolonging survival rates and improving quality of life, and treatment begins with induction and post-induction therapy, followed by hematopoietic stem cell transplant or maintenance therapy in patients ineligible for transplant. Relapse is indicated by any number of clinical signs, including hypercalcemia, renal insufficiency, anemia, new bone lesions or paraproteinemia.

This activity has been designed to update HCPs' knowledge around the current state of care in MM and improve their competence and performance in treating it.

Target Audience:

The following healthcare professionals: Hematologists and oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professional with an interest in or who clinically encounter patients with RRMM.

This program is supported by educational grants from Sanofi.

Learners may participate in this activity free of charge.

Release Date: May 27, 2021 -- Expiration Date: May 27, 2023

Faculty: Monique Hartley-Brown, MD


Faculty introduction, disclosures

Introduction content [Learning Objective #1]

  • Statistics and prognosis
  • Pathophysiology
  • RRMM diagnostic criteria and clinical features

Updates in treatment in patients with RRMM

  • Treatment prior to RRMM: Induction & post-induction regimens

·  Evaluation of treatment response and surveillance

·  RRMM goals of therapy

·  Patient and disease-related factors driving therapeutic decision-making for RRMM [Learning Objective #1]

·  Present and emerging pharmacotherapy and update in clinical trial evidence [Learning Objectives #2 & 3]

·  First relapse

·  Multiple relapse

·  Treatment-emergent adverse effects and their management [Learning Objectives #2 & 3]

  • Patient case(s) [Learning Objective #2]

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall factors impacting therapeutic decision-making in the treatment of RRMM 2.
  • Formulate a treatment plan for a patient with RRMM.
  • Describe the risk-benefit profiles of current and emerging therapies for the treatment of RRMM.


ACCME Activity #201748769


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:  Monique A. Hartley-Brown, MD, MMSc., Assistant Professor of Medicine, Donald and Barbara Zucker School of Medicine, Hofstra University, has received financial compensation for consulting work from with Bristol Myers Squibb, GlaxoSmithKline, Sanofi, KaryoPharm, Guidepoint and Janssen.

Disclosures of Educational Planners: Charles Turck, PharmD, CEO of ScientiaCME, has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by educational grants from Sanofi.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Biosimilars in the treatment of malignancies and supportive care

von Willebrand's disease: an in-depth review of management strategies

Contemporary approaches to advanced diffuse large B-cell lymphoma (DLBCL)

Metastatic colorectal cancer (mCRC) treatment: Therapeutic updates, best practices, and barriers to care